resistance-isolates-coli-106.html
DANMAP 2015 3D
107 / 144
107 danmap
2015
8. resistance in human clinical bacteria dcm more extensively and frequently. the amount of culturing and susceptibility testing performed at the different dcm will vary accordingly. all dcm reported data on mecillinam suscep- tibility and almost all reported data on ampicillin, ciprofloxacin and 3rd generation cephalosporin susceptibility, while 7 dcm reported data on sulfamethizole, 6 reported data on cefurox- ime, 5 reported data on gentamycin and meropenem suscep- tibility and 4 dcm reported data on piperacillin/tazobactam susceptibility. in 2015 there was a small decrease in ampicillin and sulfonamide resistance compared to 2014. otherwise no significant changes when comparing data from 2015 to 2014 were found. (table 8.1 and figure 8.3) in 2015, four carbapenem (meropenem) resistant and nine intermediary resistant isolates
were reported from e. coli
urine from primary health care. in 2014 those numbers were two and one, respectively. routine meropenem testing was performed at five dcm in 2015. 20 years of e. coli surveillance the surveillance of e. coli has been part of all 20 years in danmaps history and thus will be covered more extensively in this chapter. in the beginning, invasive e. coli infections were reported by two dcm: ssi and aarhus. these two laborato- ries covered 16% of the danish population. the surveillance expanded during the following 9 years and from 2004 until 2014 all dcm, except one, participated. danmap 2015 is the first danmap report with data from all danish dcm, thereby covering 100% of the danish population (figure 8.4). during the first years of danmap, it was essential to take precautions in the comparison of data from year to year and from reporting department to reporting department as well as it was neces- sary to generalize some of the observations. this was because of quite different and changing methods in the susceptibility testing and because of the rather small number of participat- ing dcms. from 2011 on, all dcms except one agreed upon us- ing the same method as a standard in the susceptibility testing following eucast principles and standards. from november 2015 all danish dcm followed eucast principles. 0 10 20 30 40 50 06 07 08 09 10 11 12 13 14 15 % resistant isolates ampicillin (n=47829) sulfonamide (n=46714) ciprofloxacin (n=47474) 3rd gen. cephalosporin (n=58345) 0 10 20 30 40 50 60 70 80 90 100 surveillance of invasive e. coli percentage of the danish population covered 0 10 20 30 40 50 60 70 80 90 100 surveillance of invasive e. coli percentage of the danish population covered figure 8.4 surveillance of invasive e. coli - percentage of the danish population covered 0 10 20 30 40 50 06 07 08 09 10 11 12 13 14 15 % resistant isolates ampicillin (n=47829) sulfonamide (n=46714) ciprofloxacin (n=47474) 3rd gen. cephalosporin (n=58345) 0 10 20 30 40 50 60 70 80 90 100 surveillance of invasive e. coli percentage of the danish population covered 0 10 20 30 40 50 60 70 80 90 100 surveillance of invasive e. coli percentage of the danish population covered figure 8.3. resistance (%) in escherichia coli urine isolates from humans in primary health care, denmark note: the number (n) in parentheses represents the number of isolates tested for susceptibility in 2015 danmap 2015 danmap 2015 0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000 0 2 4 6 8 10 12 14 16 06 07 08 09 10 11 12 13 14 15 % resistant isolates piperacillin/tazobactam (n=4592) gentamicin (n=4591) ciprofloxacin (n=4573) cefuroxime (n=4567) 3rd gen. cephalosporin (n=4561) meropenem (n=4045) number of positive bloodisolates 0 2 4 6 8 10 12 14 16 06 07 08 09 10 11 12 13 14 15 % resistant isolates ciprofloxacin (n=46133) gentamicin (n=40780) cefuroxime (n=41505) 3rd gen. cephalosporin (n=34817) number of positive blood isolates figure 8.2. resistance (%) in escherichia coli urine isolates from humans in hospitals, denmark note: the number (n) in parentheses represents the number of isolates tested for susceptibility in 2015 danmap 2015
resistance-data-dcm-108.html
